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Abstract 
Cats exposed to feline leukemia virus (FeLV) may develop different outcomes of the 
infection. However, during acute infection blood proviral and viral RNA loads of cats with 
progressive and regressive infection are not significantly different. Thus, not the overall loads 
but rather those of specific leukocyte subsets may influence the infection outcome. In the 
present study we established the methods to determine FeLV proviral and viral RNA loads in 
specific leukocyte subsets. In addition, they were applied to analyze long-term persistently 
FeLV-infected (p27positive) and FeLV exposed but nonantigenemic (p27-negative), 
nonviremic cats. In the latter animals, CD4+ and B lymphocytes exhibited the highest proviral 
loads, whereas in p27-positive cats, all leukocyte subsets showed similar high loads. In p27-
positive cats, monocytes and granulocytes bore the highest viral RNA loads, whereas only 
one p27-negative cat was positive for viral RNA in T lymphocytes. To our knowledge, this is 
the first study to investigate FeLV proviral and viral RNA loads in leukocyte subsets of FeLV 
exposed cats. The herein described methods are important prerequisites to gain a deeper 
insight into the pathogenesis of FeLV infection. 
 
Keywords 
Feline leukemia virus; Quantitative real-time PCR; FACS; Leukocytes. 
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1. Introduction 
Feline leukemia virus (FeLV) is a naturally occurring gammaretrovirus in cats. It can cause 
both cytoproliferative (e.g. lymphomas, myeloproliferative disorders) and cytosuppressive 
(e.g. immunodeficiency, anemia) diseases. Altogether, four different courses of infection have 
been described (Hoover and Mullins, 1991; Lutz et al., 1983b): (i) progressive infection with 
persistent viremia, regressive infection with (ii) transient or (iii) undetectable viremia, and (iv) 
localized FeLV-infection in tissues, such as spleen, lymph nodes, small intestine and 
mammary glands without concurrent viremia (Hayes et al., 1989; Pacitti et al., 1986). Latent 
nonproductive infection characterized by the absence of viremia and persistence of the virus 
in the bone marrow has been described in cats that ostensibly recovered from a regressive 
infection (Madewell and Jarrett, 1983; Rojko et al., 1982). Categorization of cats into these 
groups is typically accomplished by immunofluorescence assays (Hardy et al., 1973b; Hoover 
and Mullins, 1991; Jarrett et al., 1982) as well as by FeLV p27 antigen ELISA from blood 
plasma (Lutz et al., 1983a); antigenemia is a marker of infection and in most but not all cats a 
parameter for viremia (Jarrett et al., 1982). Recently, Torres and co-workers re-examined the 
FeLV-host relationship and suggested the four putative categories progressive, latent, 
regressive and abortive infection based on the results of real-time Taqman®  PCR and p27 
ELISA (Torres et al., 2005). Moreover, most recently, the spectrum of host response 
categories was also refined by investigating plasma viral RNA loads in FeLV exposed cats 
(Hofmann-Lehmann et al., In press; Hofmann-Lehmann et al., 2006). 
In spite of the common use of vaccines in veterinary practices, FeLV infections are still 
highly prevalent. A few years ago, 7% of the Swiss pet cat population was p27- as well as 
provirus-positive and exhibited high proviral loads as assessed by quantitative real-time PCR 
(Hofmann-Lehmann et al., 2001); 10% of the cats tested provirus-positive, but p27-negative. 
The latter animals had significantly lower proviral loads than the p27-positive cats (Hofmann-
Page 5 of 28 
Lehmann et al., 2001). The p27-negative but FeLV-positive status, characterized by low 
proviral load, was also demonstrated in vaccinated cats, where integration of the provirus took 
place in spite of protection from persistent viremia (Cattori et al., 2006). 
The susceptibility of cats to FeLV is age-dependent: 100% of the cats experimentally infected 
as newborn kittens and 85% inoculated at 2 weeks to 2 months of age became persistently 
viremic, but only 15% of the cats that were inoculated when they were 4 months or older 
(Hoover et al., 1976). Furthermore, the status of the immune system plays an important role in 
FeLV infection: immunosuppressive agents and chemical carcinogens have been shown to 
increase the susceptibility of adult cats to FeLV (Hoover et al., 1981; Rojko et al., 1982; 
Schaller et al., 1979). Virus neutralizing antibodies (VNA) as well as FeLV-specific cytotoxic 
T lymphocytes (CTL) play an important role in the protection of cats against FeLV. VNA can 
protect against persistent viremia (Jarrett et al., 1977), and cats with regressive viremia 
developed significantly higher antibody titers than persistently infected animals (Hofmann-
Lehmann et al., 2001). But in the majority of cases, VNA appeared at the time when cats that 
had shown transient viremia recovered (Flynn et al., 2000; Hofmann-Lehmann et al., 2006). 
In contrast, virus-specific CTL were present as early as one week postexposure, and cats 
vaccinated with a DNA vaccine were protected from infection without developing VNA 
(Flynn et al., 2000). In addition and in agreement with another study (Poulet et al., 2003), 8 
out of 10 cats vaccinated with a non-adjuvant canarypox-vectored live vaccine containing 
FeLV-A env, gag and part of pol (Eurifel®, Merial, Lyon, France) were protected from 
viremia without developing antibodies prior to experimental FeLV infection (Hofmann-
Lehmann et al., 2006). In persistently infected cats, neither VNA nor high levels of FeLV 
specific CTL were detected  (Flynn et al., 2002; Flynn et al., 2000; Hoover and Mullins, 
1991) 
Cats which developed a persistent viremia showed higher proviral and viral loads than 
transiently viremic cats, but not prior to week 2 and week 1 postexposure, respectively 
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(Hofmann-Lehmann et al., 2001; Hofmann-Lehmann et al., 2006). It thus seems that cats 
which are ultimately able to overcome the infection initially fight similar high proviral and 
viral loads in the peripheral blood like cats that become persistently infected. This led us to 
assume that not the overall viral loads in the peripheral blood, but rather different loads in 
specific leukocyte subsets influence the outcome of the infection. So far, only FeLV antigen 
loads could be measured in specific leukocyte subsets; proviral and viral RNA loads e.g. in 
antigen-negative cats could not be determined because of lack of adequate methods.  
It was thus the goal of the present study to establish a method to sort feline leukocytes by flow 
cytometry and quantify the proviral and viral RNA loads in sorted cell subsets by means of 
real-time PCR and reverse transcriptase-PCR (RT-PCR). In addition, the method was applied 
to analyze long-term infected p27-positive and p27-negative SPF cats. 
2. Materials and Methods 
2.1. Animals and virus inoculation 
Eleven three-year-old specific pathogen free, barrier-maintained cats (Charles River 
Laboratories, Lyon, France) were used in this study (Table 1). They were housed in groups in 
large rooms under optimal ethological and hygienic conditions. The cats were challenged 
intraperitoneally with FeLV-A/Glasgow-1 (family Retroviridae, subfamily Orthoretrovirinae, 
genus Gammaretrovirus, species Feline leukemia virus, strain A/Glasgow-1 (Hofmann-
Lehmann et al., 2006)) 2.5 years prior to the present investigation. Five of the cats have 
become persistently infected: they tested provirus-positive in real-time PCR (Tandon et al., 
2005), were viremic as determined by virus isolation (Jarrett and Ganiere, 1996) and 
antigenemic as determined by double sandwich ELISA (Lutz et al., 1983a). Six cats were 
provirus-positive, but nonviremic and nonantigenemic. The presence of infectious FeLV was 
determined in vitro by inoculation of heparinized plasma samples onto QN10S cells (Jarrett 
and Ganiere, 1996). Plasma VNA were measured by focus reduction of FeLV-A/Glasgow-1 
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in QN10S cells (Jarrett and Ganiere, 1996). For each blood sample, the total and differential 
white and the red blood cell counts were determined in EDTA-anticoagulated blood using an 
electronic cell counter (Cell-Dyn 3500, Abbott, Baar, Switzerland).  
2.2. Preparation and staining of leukocytes and cell sorting 
Prior to staining procedures and fluorescent activating cell sorting (FACS), peripheral blood 
mononuclear cells (PBMC) were purified from 6 ml of EDTA-anticoagulated blood by 
Percoll gradient centrifugation. Briefly, blood was centrifuged at 170 × g for 10 min at room 
temperature (RT); the plasma was removed and replaced by the same volume of Hank’s 
balanced salt solution (HBSS, Invitrogen, Basel, Switzerland). Then 4 ml of 43% Percoll 
(Amersham Biosciences, Uppsala, Sweden) was added to a 14 ml centrifuge tube (TPP, 
Trasadingen, Switzerland), and underlayered with 4 ml of 62.5% Percoll. The blood/HBSS 
solution was layered onto the Percoll gradient and the tubes were centrifuged at RT for 10 
min at 514 × g followed by 20 min at 914 × g. The mononuclear cell layer was harvested, 
washed once in HBSS and resuspended in 100 µl phosphate-buffered saline (PBS) containing 
0.5% bovine serum albumin (BSA) and 2 mM EDTA.  
Because the number of monocytes in the peripheral blood is particularly low, they were 
further enriched prior to FACS analysis using the MiniMACS Starting Kit® (Miltenyi 
Biotech, Bergisch Gladbach, Germany). Briefly, Percoll purified PBMC were labeled with an 
antibody against CD14 (TüK4, Dako Cytomation, Zug, Switzerland) recognizing monocytes 
(Bienzle et al., 2003; Willett et al., 2003), incubated for 20 min at RT and washed once with 
PBS containing 0.5% BSA and 2 mM EDTA. Cells were then stained with rat anti-mouse 
immunglobulin G (IgG) MicroBeads (Miltenyi Biotech) and run through a MS Column® 
(Miltenyi Biotech). Magnetic separation led to the collection of two fractions: CD14+ 
enriched cells and the remainder of the PBMC. The CD14+ enriched cells were labeled in the 
dark at RT for 20 min with a dichlorotriazinylaminofluorescein (DTAF)-conjugated 
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secondary antibody (F(ab) goat anti-mouse IgG [H&L], Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA). 
The rest of the PBMC were washed, resuspended in PBS containing 1% BSA and 0.1% NaN3 
and underwent staining as follows. The cell suspension was divided into aliquots and put in 5 
ml Falcon polystyrene tubes (catalog number 352058, BD Biosciences, Allschwill, 
Switzerland). Cells were then incubated for 20 min at RT in the dark with one of the 
following antibodies: an unconjugated mouse anti-feline CD4 antibody (Fel7, Southern 
Biotech, Birmingham, Alabama, USA) (Ackley et al., 1990), an unconjugated mouse anti-
feline CD8 antibody (FT2, Southern Biotech) (Klotz and Cooper, 1986), a 
fluoresceinisothiocyanate (FITC)-conjugated mouse anti-feline CD5 antibody (f43, Southern 
Biotech) recognizing T lymphocytes (Dean et al., 1991), and a Peridinin chlorophyll-a Protein 
(PerCP)-conjugated rat anti-mouse CD45R/B220 antibody (RA3-6B2, BD Bioscience) 
recognizing B lymphocytes (Brown et al., 2002; Willett et al., 2003). CD5 was used because 
in the domestic cat, CD5 expression is restricted to T cells (Ackley and Cooper, 1992; Brown 
et al., 2002). Prior to labeling of the B lymphocytes, purified rat IgG (Southern Biotech) was 
added to block all Fc receptors and prevent nonspecific binding. The CD4+ and CD8+ cells 
were labeled in the dark at RT for 20 min with a DTAF-conjugated goat anti-mouse 
secondary antibody. 
For granulocyte preparation, blood was collected in a 2 ml Vacutainer (BD Biosciences) 
prefilled with 11 glass beads (Bender&Hobein, Zurich, Switzerland) and 0.4 ml of a 6% 
dextran-solution in 0.9% NaCl. After collection, the blood was gently rotated for 5 min in 
order to remove the platelets. Defibrinated blood (100 µl) was put into a 5 ml Falcon 
polystyrene tube and incubated with a purified goat IgG (Southern Biotech) for 10 min at RT 
to block the Fc receptors. Granulocytes were then labeled for 20 min at RT with unconjugated 
mouse anti-feline granulocyte antibodies (CL35A, VMRD Inc., Pullman, WA, USA) 
followed by a DTAF-conjugated goat anti-mouse secondary antibody for an additional 20 min 
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at RT in the dark. Finally hypotonic formic acid (550 µl) and, after 10 sec, 250 µl of a salt 
solution (57 mM Na2CO3, 248 mM NaCl and 220 mM Na2SO4 in 1L ddH2O) were added to 
the tube while vortexing to lyse the red blood cells. 
In each experiment, negative controls were included as follows. For indirect staining, cells 
were incubated with only the secondary antibody. As a control for direct staining, cells were 
incubated with an isotype-matched non-binding antibody: for CD5+ lymphocytes, FITC-
conjugated mouse IgG1 isotype control (clone 15H6, Southern Biotech), and for B 
lymphocytes, PerCP-conjugated rat IgG2a  monoclonal immunoglobulin isotype control (clone 
R35-95, BD Bioscience).  
Stained cells were stored at 4°C and filtrated through a 50 µm filter (LabForce, Nunningen, 
Switzerland) immediately prior to sorting on a BD FACS Aria, and analyzed using the BD 
FACS Diva software™. On the basis of the forward versus side scatter, 10,000 cells were 
gated to set the fluorescence cutoff; this was set so that less than 2% of the negative events 
were included in the positive analysis region. Cells were sorted into PBS and frozen at -80°C 
until DNA extraction. 
2.3. DNA extraction and FeLV/GAPDH real-time PCR 
DNA was extracted from sorted cells and from 100 µl EDTA-anticoagulated blood using the 
QIAmp® DNA Micro Kit (Qiagen, Hombrechtikon, Switzerland). DNA was eluted in 50 µl 
elution buffer and stored at -80°C until use. FeLV provirus was quantified by real-time PCR 
as described (Tandon et al., 2005). In addition, feline glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), of which one copy of a pseudogene is present in the genomic DNA 
of feline cells (Molia et al., 2004), was quantified in each sample by real-time PCR 
(Leutenegger et al., 1999). FeLV proviral copies per cell were obtained by dividing the FeLV 
copy number by the GAPDH copy number (Cattori et al., 2006). 
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2.4. RNA extraction and FeLV/GAPDH real-time RT-PCR 
From sorted cells, viral RNA was extracted from the first flow-through (250 µl) of the 
respective DNA extraction using the MagnaPure LC mRNA Isolation Kit (Roche, Basle, 
Switzerland). The same kit was used to extract RNA from 100 µl EDTA-anticoagulated 
blood. In addition, viral RNA was extracted from 280 µl of plasma with the QIAamp® Viral 
RNA Mini Kit (Qiagen). RNA samples were stored at -80°C until use. FeLV viral RNA loads 
of the leukocyte subsets as well as of the EDTA-anticoagulated blood and plasma were 
determined as published (Tandon et al., 2005). Viral RNA loads in leukocyte subsets and 
whole blood were normalized to GAPDH mRNA. Plasma viral RNA loads were calculated as 
copies per ml of plasma. 
2.5. Statistics 
Data were compiled and analyzed with Prism software (GraphPad, San Diego, CA). For the 
comparison of FeLV proviral and viral RNA loads among different leukocyte subsets, the 
Kruskal-Wallis 1-way ANOVA by Ranks (pKW) and the Dunn’s post test (pD) were used. 
Loads and cell numbers of p27-negative and p27-positive cats were compared using the 
Mann-Whitney U Test (pMWU). Differences were considered significant if p < 0.05.  
3. Results 
3.1. Characteristics of the cats 
Infectious FeLV was found in the p27-positive, but not in the p27-negative cats (Table 1). 
Plasma viral RNA was detected in the p27-positive and in one of the p27-negative animals 
(Table 1). Within the p27-negative cats, five out of five animals tested developed VNA; in 
contrast, none of the p27-positive cats had VNA. No significant difference was found in total 
leukocyte, lymphocyte, granulocyte, and monocyte counts between p27-positive and p27-
negative cats (Table 2). When the numbers of cells that had been sorted from a constant input 
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blood volume were compared, long-term p27-positive cats had slightly lower CD4+ and CD5+ 
T-cell counts than p27-negative cats (both pMWU = 0.0823). No difference or tendency was 
found when the numbers of the other sorted cell subsets were compared.  
3.2. Proviral loads in specific leukocyte subsets 
Cats that were p27-positive had significantly higher blood proviral loads (median load = 
3.74×106 copies/106 cells) than p27-negative cats (median load = 4.68×101 copies/106 cells; 
pMWU = 0.0043; Fig. 1). In addition, a significant difference was also found when the 
proviral loads were calculated per ml of blood: p27-positive cats had higher loads (median 
load = 1.30x107 copies/ml) than p27-negative cats (median load = 1.53x102 copies/ml; 
pMWU = 0.0043). Proviral loads of leukocyte subsets were significantly different within the 
p27-negative cats, in that the CD4+ cells had significantly higher loads (median load = 
1.15×102 copies/106 cells) than the granulocytes (median load = 0 copies/106 cells; pKW = 
0.0112; pD < 0.05; (Fig.1). A significant difference was also found between the proviral loads 
of lymphocytes (median load = 5.98×101 copies/106 cells) and the remaining white blood cells 
(monocytes and granulocytes, median load = 0 copies/106 cells; pMWU = 0.0260). In the 
group of p27-positive cats, no significant difference was found among proviral loads of 
different leukocyte subsets (pKW = 0.0622; Fig.1). 
3.3. Viral RNA loads in specific leukocyte subsets 
A significant difference was found between blood viral RNA loads of p27-positive (median 
load = 6.49 copies/GAPDH copy) and p27-negative cats (median load = 0 copies/GAPDH 
copy; pMWU = 0.0043; Fig. 2) as well as in plasma viral RNA loads between p27-positive 
(median load = 1.23x108 copies/ml) and p27-negative cats (median load = 0 copies/ml; 
pMWU = 0.0043; Table 2).  
In the group of the p27-positive cats, all leukocyte subsets were highly positive for FeLV 
RNA (Fig. 2). The viral RNA loads of the leukocyte subsets within this group were 
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significantly different and CD4+ cells had significantly lower loads (median load = 3.9×10-1 
copies/GAPDH copy) than monocytes (median load = 4.83 copies/GAPDH copy; pKW = 
0.0031; pD < 0.01). Viral RNA loads of monocytes and granulocytes (median load = 3.46 
copies/GAPDH copy) were significantly higher than the loads in lymphocytes (median load = 
1.36 copies/GAPDH copy; pMWU = 0.0079). Viral RNA was only found in T lymphocytes 
and in the plasma of one of the six p27-negative cats (Fig.2). 
4. Discussion 
To our knowledge, this is the first study to quantify FeLV DNA and RNA loads in different 
feline leukocyte subsets of FeLV exposed cats. Our results demonstrate that FeLV proviral 
and viral RNA loads are distinctively distributed among the leukocyte subsets of long-term 
infected p27-negative and p27-positive cats, respectively.  
In accordance with earlier reports (Hofmann-Lehmann et al., 2001; Hofmann-Lehmann et al., 
2006; Torres et al., 2005), long-term p27-positive cats had higher overall FeLV proviral and 
viral RNA loads than p27-negative cats. The cats under investigation had been infected for 
2.5 years with FeLV-A/Glasgow-1; while p27-positive and p27-negative cats had still similar 
total peripheral white blood counts, the p27-positive cats had somewhat reduced CD4+ T-cell 
numbers. Although it may be assumed that these results were not very precise because the 
method was not primarily designed to measure absolute cell numbers, they are in agreement 
with an earlier investigation with the same virus where CD4+ T-cell counts were found 
reduced in long-term persistently FeLV-infected cats (Hofmann-Lehmann et al., 1997). The 
described method for the determination of FeLV proviral and viral RNA loads in individual 
leukocyte subsets combines flow cytometric cell sorting with sensitive real-time TaqMan 
PCR and the loads are normalized against GAPDH copy numbers as a measure for the cell 
number (pseudogene) and the transcription level of a house keeping gene, respectively. Thus, 
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the reduced CD4+ T-cell counts of persistently infected cats did not influenced our 
investigations of absolute FeLV loads in individual cell subsets.  
Rojko and coworkers have described six sequential phases of FeLV infection (Rojko et al., 
1979). In cats with regressive viremia, the control of the virus seems to take place at phase 3 
(viral replication in lymphoid germinal cells in lymphoid tissues throughout the body) and 
phase 4 (viral replication in bone marrow neutrophil and platelet precursor cells and crypt 
epithelium). These cats exhibit only a first cell-associated viremia in lymphocytes and 
monocytes, but not a second viremia of bone marrow origin, which is characterized by the 
presence of FeLV group-specific antigen (GSA, gag gene coded protein p27) in neutrophils 
and platelets (Hardy et al., 1973a; Hoover et al., 1977). In agreement with that, our data 
indicate that in regressively infected cats, no second viremia and therefore no infection of 
granulocytes took place. However, our study exceeds these data in that beside the lack of viral 
protein expression in granulocytes of p27-negative cats (Rojko et al., 1979), also no provirus 
was detectable in this leukocyte subset. In addition, we demonstrate that in cats with 
undetectable antigenemia, certain cell subsets, in particular CD4+ and B lymphocytes may 
still be provirus positive even 2.5 years after FeLV exposure. 
Most former studies which aimed to identify viral target cells used immunofluorescence to 
detect FeLV GSA in blood leukocytes, lymph nodes, bone marrow and epithelial tissue 
(Hardy et al., 1973a; Hoover et al., 1987; Hoover et al., 1977; Rojko et al., 1978; Rojko et al., 
1979). In the present study, we used new sensitive methods to find productively infected 
white blood cells. Cats with productive infection showed higher viral RNA loads in 
monocytes and granulocytes when compared to those in lymphocytes. Remarkably, in 
persistently infected cats lymphocytes and in particular CD4+ T cells were infected to a lesser 
degree than other cell subsets although CD4+ cells were found to be decreased in long-term 
FeLV infection (see above and (Hofmann-Lehmann et al., 1997)). It may thus be speculated 
that either not a direct effect of FeLV infection leads to the destruction of CD4+ lymphocytes 
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or only a subset of these cells reacts particularly sensitive to FeLV infection. The finding that 
particularly monocytes and granulocytes but to a lesser degree lymphocytes are infected is in 
agreement with other studies: The most frequent and most intense specific fluorescence was 
found in the cytoplasm of neutrophils, monocytes and in platelets in blood smears of viremic 
cats, either naturally or experimentally infected with FeLV (Hardy et al., 1973b; Hoover et 
al., 1977). Quackenbush and coworkers have shown that in cats chronically infected with 
FeLV-FAIDS 61E or acutely infected with FeLV-FAIDS 61E/C, almost all of the feline 
myeloid antigen positive monocytes and granulocytes expresses FeLV p27 (85 – 93%), but 
only a fraction (20 – 60%) of CD4+, CD8+ and IgG+ lymphocytes (Quackenbush et al., 1996). 
Because of the good agreement with published data, we assume that our method primarily 
detects productively infected cells, although we cannot completely rule out that some of the 
viral RNA sequences detected in granulocytes by real-time TaqMan PCR originated from 
viral particles that had been take up via phagocytosis.  
In the group of the p27-negative cats, only one cat was positive for plasma viral RNA and for 
cell-associated viral RNA in T lymphocytes. The presence of viral RNA might be indicative 
for replication of the virus in this particular cat, although the animal tested negative in p27 
ELISA and virus isolation. There might be several explanations for this discrepancy. Firstly, 
the sensitivity of p27 ELISA and virus isolation might be lower than that of the RT-PCR. 
Therefore p27 ELISA and virus isolation could give false negative results for cats with a very 
low-level infection. Secondly, the cat might have had a localized infection and virus particles, 
which were defective and not replication competent were released into the peripheral blood. 
These particles might not be detectable by p27 ELISA or virus isolation. In contrast, the 
presence of free RNA in the plasma seems less likely due to low stability. 
Enriched peripheral blood polymorphonuclear leukocytes of FeLV-infected cats show a 
significantly lower chemiluminescence and a decreased phagocytic and oxidative burst 
activity than those of noninfected control cats (Hoffmann-Jagielska et al., 2005; Lafrado and 
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Olsen, 1986; Lewis et al., 1986). This was also the case for neutrophils of FeLV-exposed cats, 
which were nonviremic (Lafrado and Olsen, 1986). The latter observation could be explained 
by the finding that purified viral protein p15 acted as a immunosuppressive agent in vitro 
(Hebebrand et al., 1979; Mathes et al., 1979) and a synthetic analogue of p15E was 
demonstrated to suppress the respiratory burst of human monocytes (Harrell et al., 1986). In 
addition, data presented by Lafrado and coworkers (Lafrado et al., 1987) indicate that 
ultraviolet light-inactivated FeLV and the purified protein p15E impairs the function of feline 
neutrophils. Thus, not the productive infection of granulocytes, but rather the presence of viral 
proteins or parts of viral proteins seems to affect the function of neutrophils in FeLV-exposed 
cats. In agreement with this, it may be assumed that also in the nonviremic cats of the present 
study, the granulocyte function might have been decreased although the cells were FeLV 
provirus-negative. 
In p27-positive cats, the FeLV proviral loads in most of the cells exceeded 1 copy per cell, 
whereas in the majority of p27-negative cats, some leukocyte subsets, such as CD8+ 
lymphocytes, monocytes and granulocytes, were found provirus-negative. This was even the 
case when up to 1.7×105 granulocytes were sorted and a very sensitive real-time PCR assay 
(Tandon et al., 2005) (detection limit: 1 copy/5 µl reaction) was used. The inability to detect 
provirus in these cells could be explained by the fact that the proviral loads were nevertheless 
below the detection limit of our assay. However, provirus was detectable in other leukocyte 
subsets despite of very low cell numbers (minimum of 5×104 cells). In addition, our data are 
in agreement with the findings of Rojko and coworkers who have shown that FeLV GSA 
cannot be detected in neutrophils of transiently infected cats, but in those of persistently 
infected cats (Rojko et al., 1979).  
In conclusion, this study was performed to establish the necessary methods to assess proviral 
and viral RNA loads in feline cell subsets and to investigate the magnitude of the FeLV 
infection in different cell subsets of persistently infected and nonviremic FeLV exposed cats. 
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Using sensitive molecular methods, the proviral and viral RNA loads of specific leukocyte 
subsets were analyzed and significant differences between and within leukocyte subsets of 
long-term infected, p27-positive and p27-negative cats were found. The particular distribution 
of FeLV provirus and viral RNA during long-term infection may originate from differences  
in the very early phase of the infection, which seems crucial for the clinical outcome. To 
further address the hypothesis that the initial loads in specific leukocyte subsets influence the 
course of infection, the proviral and viral RNA loads should be investigated during the very 
first few weeks after infection.  
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Table 1  
Virological and immunological characteristics of p27-positive and p27-negative cats 
Cat ID  11 12 20 49 57 69 19 32 10 43 38 
 
p27-ELISA (%)  0 0 0 0 0 0 83 71 60 109  75 
Virus isolation  nega neg neg neg NDb neg posc pos pos pos pos 
Titer of VNA  1:32 1:32 1:32 1:32 ND 1:32 0 0 0 0 0 
Plasma viral RNAd  2.58×104 0 0 0 0 0 1.1×108 1.2×107 8.9×107 4.0×108 4.1×108  
aneg = negative, bND = not done, cpos = positive, dFeLV RNA copies/ml plasma 
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Table 2 
Hematological characteristics of p27-positive and p27-negative cats 
Cat ID  11 12 20 49 57 69 19 32 10 43 38 
 
Leukocytes (103/µl) 3.22 3.93 8.45 7.99 5.60 9.05 4.27 3.53 4.09 5.09 4.78 
Lymphocytes (103/µl) 1.02 1.52 5.48 3.90 1.43 4.02 2.52 1.19 0.98 1.02 1.13 
Monocytes (103/µl)  0.09 0.17 0.09 0.34 2.00 0.45 0.10 0.25 0.02 0.11 0.22 
Granulocytes (103/µl) 2.11 2.24 2.88 3.74 4.03 4.59 1.65 2.09 3.09 3.96 3.44 
Erythrocytes (106/µl) 7.89 6.80 7.91 9.08 6.96 8.82 7.73 8.00 7.58 7.45 8.14 
Hemoglobin (g/dl)  11.9 11.3 13.0 12.5 10.9 12.6 11.3 12.2 12.2 11.2 12.7 
PCV (%)a  33.6 32.1 36.4 37.9 32.0 37.7 32.8 36.0 35.2 32.2 36.2 
a PCV = packed cell volume 
 
 
 
Page 26 of 28 
Blood CD4+ CD8+ CD5+ B Mc Gc
Neg
0
2
4
6
8
L
o
g
 
F
e
L
V
 
p
r
o
v
i
r
a
l
 
c
o
p
i
e
s
/
1
0
6
 
c
e
l
l
s
A
L
o
g
 
F
e
L
V
 
p
r
o
v
i
r
a
l
 
c
o
p
i
e
s
/
1
0
6
 
c
e
l
l
s
Blood CD4+ CD8+ CD5+ B Mc Gc
Neg
0
2
4
6
8
B
Fig. 1: FeLV proviral loads in EDTA-anticoagulated whole blood (blood) and specific leukocyte subsets of p27-positive (A) 
and p27-negative (B) cats. 
CD4+, CD4+ lymphocytes; CD8+, CD8+ lymphocytes; CD5+, CD5+ lymphocytes; B, B lymphocytes; Mc, monocytes; 
Gc, granulocytes. The figure legend depicts the symbols corresponding to the different cats as listed in Tables 1 and 2. 
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Fig. 2: FeLV viral RNA loads in EDTA-anticoagulated whole blood (blood) and specific leukocyte subsets of p27-positive (A) 
and p27-negative (B) cats. 
CD4+, CD4+ lymphocytes; CD8+, CD8+ lymphocytes; CD5+, CD5+ lymphocytes; B, B lymphocytes; Mc, monocytes; 
Gc, granulocytes. The figure legend depicts the symbols corresponding to the different cats as listed in Tables 1 and 2.
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